In the paper entitled "Lp-PLA2 and Risk of Stroke", Philip Gorelick, MD, MPH, Professor and Head of Neurology, University of Illinois College of Medicine, provides a review of several prospective epidemiological studies of Lp-PLA2 and stroke risk, and states that "determining patients at high risk for stroke may be challenging because total and LDL cholesterol may not predict stroke risk very well." The panel recommends testing Lp-PLA2 to help identify moderate-risk individuals who may be at high risk of stroke for whom more intensive lifestyle and pharmacotherapies may be indicated to reduce stroke and other major vascular events.
In his paper entitled "Lp-PLA2: An Independent Predictor of Coronary Events in Primary and Secondary Prevention," Jeffrey Anderson, MD, Professor of Medicine (Cardiology), University of Utah School of Medicine reported: "Lp- PLA2 appears to be highly specific for high atherosclerotic disease activity, independent and additive to traditional risk factors and metabolic syndrome. As such, Lp-PLA2 could alert the clinician to initiate proven strategies for coronary event and stroke reduction."
Both a PDF of the supplement and a searchable text version can be found on The American Journal of Cardiology website at: http://www.ajconline.org/issues/contents?issue_key=S0002-9149(08)X0017-7
diaDexus, Inc., the educational sponsor of this supplement, is a
privately held diagnostics company based in South San Francisco, C
|SOURCE diaDexus, Inc.|
Copyright©2008 PR Newswire.
All rights reserved